Ladder Bio

Ladder Bio Inc., headquartered in Blue Bell, Pennsylvania, is a therapeutics company pioneering the development of Spiroligomer molecules, a novel class of synthetic, ladder-shaped peptide-like compounds. Founded in 2020 as a spinout from Temple University research, the company was formerly known as ThirdLaw Molecular before rebranding in November... 2025. Ladder Bio's proprietary Spiroligomer platform engineers structurally preorganized, sequence-defined molecules designed to combine the potency and specificity of biologics with the stability, oral availability, and cell penetration characteristics of small molecules. These compounds are engineered to engage challenging biological targets with high affinity and selectivity, addressing therapeutic needs where conventional modalities have fallen short. The company focuses on developing oral drug candidates for inflammatory and autoimmune diseases, leveraging rational molecular design integrated with computational discovery methods. Ladder Bio's technology platform enables the creation of synthetic therapeutics that can selectively bind target proteins while offering advantages in cost, storage, and delivery compared to traditional biologics. The company is led by CEO Eric Heil and founder Dr. Christian Schafmeister, who serves as Chief Scientific Officer and President.Read More